Immucor Places 100th Blood Automation System in North America Company Reaches Milestone Ahead of Schedule
Wednesday December 15, 8:05 am Eastern Time
NORCROSS, Ga., Dec. 15 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD - news), the leading manufacturer of blood bank reagents and related products in North America, today announced that it has placed its 100th blood bank automation instrument in North America, a significant strategic milestone for the Company.
''Reaching the 100th system milestone this early in our product introduction is a testimony to the acceptance of automation in the blood bank market,'' commented Edward L. Gallup, president of Immucor. ''We are pleased to announce that it took less than six months to go from 50 to 100 instrument placements, which puts us ahead of the placement rate needed to achieve our internal sales forecasts. The annual consumable reagent volume associated with the first 100 instrument placements will amount to more than 50 million tests of Immucor's high margin Capture products.''
''Though automation is gaining increasing acceptance in the blood transfusion industry, the potential market place for automated products remains largely untapped,'' Gallup continued. ''The high rate of growth in our placements is due, in part, to an increased close rate from our recently reorganized sales force.''
''It is also due to the fact that the rapidly growing family of automation users has demonstrated that Immucor's products not only improve the safety of blood supplies, they deliver substantial labor savings as well. This clearly illustrates that our technology is leading the evolution towards an error-free blood transfusion process.''
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers throughout the world to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all market segments.
For more information on Immucor, please visit the company's website at www.immucor.com .
This press release may contain forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. In particular, instrument placements and reagent volumes achieved to date are not necessarily indicative of future performance. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form
10-Q.
SOURCE: Immucor, Inc.
|
